Yes Upxdn there was brief discussion on that front. Your 2nd...

Yes Upxdn there was brief discussion on that front. Your 2nd hand source was correct! I didn’t catch the whole question from the crowd about a dual listing but Tribe’s response was (paraphrase) “yes i agree that we will have to consider taking the company to an international market. I don’t agree that a dual listing is the correct approach, I have seen other companies come unstuck by dual listing. We will have to consider moving to another financial market as the Australian market doesn’t seem to value biotech companies.” I didn’t catch if he was referring to head office or listing but assumed it was head office. This all included discussion about what the company needs to do to attract the interest of Australian market and a name change was also touted by some investors in an endeavour to attract analyst attention again by resetting the company.

An interesting consideration, in that the preferred approach would be to attract interest of Pharmaco and many of the targets may be in Asia region, but going to the US financial markets might be in relation to attracting a buyout. Interesting days.